Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
5 FINANCING ROUNDS
Description

An oral therapy approved in 51 countries worldwide, including member states of the European Union and the USA. The medication is for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) to reduce blood Phe levels in patients. It is a pharmaceutical formulation of BH4, the natural cofactor for the PAH enzyme, which stimulates activity of the residual PAH enzyme to metabolize Phe into tyrosine. It is to be used in conjunction with a Phe-restricted diet.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Other Industries
Drug Discovery
Primary Office
  • Darmstadt
  • Germany

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request full access to PitchBook

Merck Serono & BioMarin Pharmaceutical (Kuvan Rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Merck Serono & BioMarin Pharmaceutical (Kuvan Rights)‘s full profile, request access.

Request full access to PitchBook